{"manuscript_title":"<b>Extracorporeal Photopheresis Versus FAM Therapy in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans</b><b>: </b><b>What We Understand and What Remains Unclear</b>","abstract":"<b>A</b><b>bstract</b> Chronic graft-versus-host disease (cGVHD) is a significant late complication following allogeneic hematopoietic cell transplantation (HCT), with bronchiolitis obliterans syndrome (BOS) being the primary lung manifestation associated with this condition. BOS results from a complex interplay of immune responses, environmental exposures, and transplant-related complications, leading to irreversible damage and scarring of the small airways in the lungs. Extracorporeal photopheresis (ECP) is one modality that has shown promise in slowing lung function decline in patients with progressive BOS, particularly after lung transplantation. Moreover, various research has underscored the comparison between ECP and FAM therapy for BOS, highlighting the necessity of adjusting therapies following immunosuppressive therapy. FAM therapy, a combination of inhaled Fluticasone, Azithromycin, and Montelukast, is increasingly recognized as a treatment option for BOS, especially after HCT. This study seeks to assess the efficacy of ECP compared to FAM therapy in the management of BOS in patients following HCT. The study used databases like PubMed, Embase, Cochrane Library, and ClinicalTrials.gov, as well as reference lists of relevant studies. The selection criteria included prospective trials that compared ECP with FAM treatment in patients experiencing BOS after HCT.","keywords":["Extracorporeal photopheresis","FAM therapy","bronchiolitis obliterans syndrome","hematopoietic cell transplantation"]}